Core Viewpoint - *ST Tianshan (300313.SZ) reported significant growth in sales of live livestock, indicating a strong performance in the core business and a strategic expansion in livestock breeding [1] Sales Performance - In October 2025, the company sold 1,367 heads of live livestock, generating sales revenue of 13.3484 million yuan [1] - The sales volume and revenue showed a quarter-on-quarter increase of 364.97% and 365.64% respectively [1] - Year-on-year changes were also substantial, with sales volume and revenue increasing by 354.15% and 242.54% respectively [1] Strategic Expansion - The company is systematically expanding its livestock breeding scale based on a comprehensive assessment of the overall live cattle market, strategic layout, and funding [1] - Continuous efforts are being made to promote the development of this core business [1]

Group 1 - The company *ST Tianshan (300313)* reported sales of 1,367 live livestock in October 2025, generating revenue of 13.3484 million yuan [1] - The sales volume and revenue showed significant month-on-month increases of 364.97% and 365.64% respectively [1] - Year-on-year changes also indicated substantial growth, with sales volume and revenue increasing by 354.15% and 242.54% respectively [1]

三、风险提示 （一）上述数据未经审计，可能与公司定期报告披露的数据存在差异，因此 上述数据仅作为阶段性数据供投资者参考。 证券代码：300313 证券简称：*ST天山 公告编号：2025-063 新疆天山畜牧生物工程股份有限公司 2025 年 10 月活畜销售情况简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、2025 年 10 月销售情况简报 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）2025 年 10 月销 售活畜 1,367 头，销售收入 1,334.84 万元，环比变动分别为 364.97%、365.64%； 同比变动分别为 354.15%、242.54%。 二、原因说明 基于对整体活牛市场行情、公司战略布局与资金等情况的综合考量，公司正 有序扩大活畜养殖规模，持续推动该核心业务发展。考虑到活畜养殖中，因用途 不同及客户需求差异，活畜的养殖周期存在客观区别，公司将结合生产经营规划 和市场行情变化趋势，适时调整出栏时间。本月活畜销售数量及收入环比、同比 上升的主要原因是本月出栏量高于上月及上年同期。 （二）上述披露仅包含公司活畜销售情 ...

Group 1 - The company sold 1,367 live livestock in October 2025, generating sales revenue of 13.3484 million yuan [1] - The month-on-month sales volume and revenue increased by 364.97% and 365.64% respectively [1] - Year-on-year sales volume and revenue saw significant growth, with increases of 354.15% and 242.54% respectively [1]

Core Insights - The aquaculture sector experienced a 1.0% increase on October 31, with Tianyu Biological leading the gains [1] - The Shanghai Composite Index closed at 3954.79, down 0.81%, while the Shenzhen Component Index closed at 13378.21, down 1.14% [1] Aquaculture Sector Performance - Tianyu Biological (603717) closed at 9.16, up 4.93% with a trading volume of 254,000 shares and a transaction value of 234 million [1] - Huaying Agriculture (002321) closed at 2.90, up 4.69% with a trading volume of 654,900 shares and a transaction value of 188 million [1] - Other notable performers include *ST Tianshan (300313) up 3.34%, Luoniushan (000735) up 2.37%, and Xiaoming Co. (300967) up 1.65% [1] Capital Flow Analysis - The aquaculture sector saw a net inflow of 290 million from institutional investors, while retail investors experienced a net outflow of 190 million [2] - Major stocks like Muyuan Foods (002714) had a net inflow of 203 million, while Wens Foodstuffs (300498) had a net inflow of 61 million [3] - The overall trend indicates a shift in capital, with institutional investors showing confidence in the sector while retail investors are withdrawing [2][3]

Core Points - The aquaculture sector experienced a decline of 1.31% on October 30, with Tianyu Biology leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Stock Performance - Yisheng Co. (002458) closed at 9.03, up 0.33% with a trading volume of 97,800 shares and a turnover of 88.43 million yuan [1] - Xiantan Co. (002746) closed at 6.31, up 0.32% with a trading volume of 154,800 shares and a turnover of 97.81 million yuan [1] - Tianyu Biology (603717) closed at 8.73, down 3.64% with a trading volume of 155,200 shares and a turnover of 137 million yuan [2] - Huaying Agriculture (002321) closed at 2.77, down 3.15% with a trading volume of 424,400 shares and a turnover of 119 million yuan [2] Capital Flow - The aquaculture sector saw a net outflow of 188 million yuan from institutional investors, while retail investors had a net inflow of 141 million yuan [2] - The main capital inflow and outflow for specific stocks included: - Jingji Zhinnong (000048) had a net inflow of 19.99 million yuan from main capital [3] - Wens Foodstuff Group (300498) had a net inflow of 7.96 million yuan from main capital [3] - Yisheng Co. (002458) had a net inflow of 3.79 million yuan from main capital [3]

Group 1 - *ST Tianshan reported a revenue of approximately 58.48 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 44.98% [1] - The net profit attributable to shareholders of the listed company was a loss of approximately 11.7 million yuan [1] - The basic earnings per share showed a loss of 0.0374 yuan [1] Group 2 - As of the report, the market capitalization of *ST Tianshan is 2.6 billion yuan [2] - The Chinese innovative drug sector has generated 80 billion US dollars in overseas licensing this year [2] - There is a contrast in the biopharmaceutical secondary market being active while the primary market is facing challenges in fundraising [2]

Group 1 - The core point of the article is that *ST Tianshan announced the transfer of its 100% stake in Baluruk Livestock Co., Ltd. to Xiamen Yunjihuo Enterprise Network Technology Co., Ltd. for a nominal price of 1 RMB due to the poor long-term operating conditions of Baluruk and its insolvency [1] - The decision is part of the company's strategy to optimize its asset structure and focus on core business operations [1] - As of the first half of 2025, *ST Tianshan's revenue composition is 54.91% from the livestock industry and 45.09% from asset leasing [1] Group 2 - As of the report, *ST Tianshan has a market capitalization of 2.6 billion RMB [2] - The article highlights the booming secondary market for biopharmaceuticals in China, with 80 billion USD in overseas licensing deals this year [2] - There is a contrast noted between the hot secondary market and the cooling fundraising environment in the primary market for biopharmaceuticals [2]

新疆天山畜牧生物工程股份有限公司 第六届董事会独立董事专门会议第一次会议决议 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）第六届董事会独 立董事专门会议第一次会议（以下简称"本次会议"）通知及会议材料于 2025 年 10 月 17 日以书面通知和电子邮件方式发出，于 2025 年 10 月 21 日以通讯表 决方式召开。本次会议经公司全体独立董事推举由独立董事刘宗柳先生主持，应 到独立董事 3 人，实到独立董事 3 人。 本次会议的通知、召集、召开和表决程序符合《中华人民共和国公司法》《上 市公司独立董事管理办法》《公司章程》《公司独立董事专门会议工作制度》等 有关规定，会议合法有效。 经与会独立董事审议，以记名投票表决方式审议通过了如下议案： 审议通过《关于转让全资孙公司股权暨关联交易的议案》 二〇二五年十月二十一日 经审核，独立董事认为：本次公司转让新疆巴尔鲁克牧业有限责任公司 100% 股权暨关联交易事项符合公司的发展利益和业务需要，符合公司及股东利益，不 存在损害公司特别是中小投资者利益的行为。同时，公司应遵照《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 ...

证券代码：300313 证券简称：*ST天山 公告编号：2025-060 新疆天山畜牧生物工程股份有限公司 第六届董事会第二次会议决议公告 表决结果：同意 9 票、反对 0 票、弃权 0 票。此议案获得通过。 具体内容详见公司同日在中国证监会指定的创业板信息披露网站巨潮资讯 网（www.cninfo.com.cn）发布的《2025 年第三季度报告》。 1 新疆天山畜牧生物工程股份有限公司（以下简称"公司"）第六届董事会第 二次会议（以下简称"本次会议"）通知及会议材料于 2025 年 10 月 21 日以书 面通知和电子邮件方式发出。本次会议于 2025 年 10 月 24 日以通讯表决方式召 开，本次会议应参加董事 9 人，实际参加董事 9 人。本次会议的通知、召开、召 集和表决程序符合《中华人民共和国公司法》及《新疆天山畜牧生物工程股份有 限公司章程》的有关规定，会议决议合法、有效。 二、董事会会议审议情况 本次会议以记名方式投票表决，审议通过以下事项： （一）审议通过《公司 2025 年第三季度报告》 经审议，董事会认为《公司 2025 年第三季度报告》符合相关法律法规和深 圳证券交易所的规定，真实、准 ...